All In Biotech

Drug Trial Radar · NCT07832630

Saruparib in HRDsig+ Solid Tumors

A Phase II Study of Saruparib in Patients With Platinum-Sensitive, HRDsig+ Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

124

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Nov 1, 2029

Study completion Nov 1, 2030

Sponsor

Lead sponsor
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AstraZeneca; Basser Center for BRCA
First posted
Sep 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency Signature (HRDsig) positive tumor by the investigational FoundationOne®CDx clinical trial assay.

Conditions

  • Malignant Neoplastic Disease (Disorder)

Interventions

  • SaruparibDrug

    Saruparib (AZD5305) 60mg PO daily

  • FoundationOne®CDxDiagnostic test

    Tumors will be tested for positive HRDsig tumor by the investigational FoundationOne®CDx clinical trial assay.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best objective response as determined by RECIST v.1.1Time frame: From baseline through documented disease progression (RECIST v1.1) or death from any cause, whichever occurs first, up to 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.